Dashboard
Manage Tickers

CLRB


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cellectar-biosciences-q3-eps-141-beats-253-estimate
Cellectar Biosciences Q3 EPS $(1.41) Beats...
11/13/2025 12:03:04

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of...

earnings-scheduled-for-november-13-2025
Earnings Scheduled For November 13, 2025
11/13/2025 11:11:32

earnings-outlook-for-cellectar-biosciences
Earnings Outlook For Cellectar Biosciences
11/12/2025 17:03:34

cellectar-biosciences-receives-rare-pediatric-disease-designation-from-fda-for-iopofosine-i-131-in-relapsed-or-refractory-pediatric-high-grade-glioma
Cellectar Biosciences Receives Rare Pediat...
10/27/2025 12:32:57

cellectar-biosciences-presented-preclinical-data-on-clr-121225-a-novel-actinium-based-alpha-emitter-for-pancreatic-ductal-adenocarcinoma-which-has-completed-ind-enabling-studies-and-may-advance-to-a-phase-1-trial
Cellectar Biosciences Presented Preclinica...
10/14/2025 12:37:11

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develop...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 17:06:17

clearsign-receives-initial-cfd-and-engineering-order-from-supermajor-refiner-as-first-phase-of-process-heater-retrofit-for-total-of-32-clearsign-core-burners
ClearSign Receives Initial CFD And Enginee...
10/07/2025 12:36:18

cellectar-biosciences-secures-58m-in-gross-proceeds-through-institutional-warrant-exercise
Cellectar Biosciences Secures $5.8M In Gro...
10/07/2025 12:33:33

cellectar-eyes-2027-eu-launch-as-ema-backs-conditional-approval-path-for-its-blood-cancer-drug
Cellectar Eyes 2027 EU Launch As EMA Backs...
10/06/2025 11:08:17

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develop...

cellectar-biosciences-highlights-presentations-at-american-association-for-cancer-research-special-conference-on-discovery-and-innovation-in-pediatric-cancer-sept-25-28
Cellectar Biosciences Highlights Presentat...
09/30/2025 12:38:31

evestia-to-provide-cellectar-with-full-cro-services-for-upcoming-phase-1b-study-evaluating-clr-125-for-treatment-of-triple-negative-breast-cancer
Evestia To Provide Cellectar With Full CRO...
09/24/2025 12:34:44

Cellectar Biosciences, Inc. ("Cellectar") (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the...

cellectar-biosciences-to-present-preclinical-data-on-novel-pancreatic-cancer-therapy-at-aacr-conference
Cellectar Biosciences To Present Preclinic...
09/03/2025 12:08:14

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develo...

cellectar-to-present-interim-phase-1b-data-on-iopofosine-in-pediatric-brain-cancer-at-aacr-conference
Cellectar To Present Interim Phase 1b Data...
08/27/2025 12:09:38

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develop...

cellectar-biosciences-q2-eps-339-beats-398-estimate
Cellectar Biosciences Q2 EPS $(3.39) Beats...
08/14/2025 11:22:46

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(3.39) per share which beat the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

a-peek-at-cellectar-biosciencess-future-earnings
A Peek at Cellectar Biosciences's Future E...
08/13/2025 16:03:33

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/30/2025 12:08:36

cellectar-biosciences-has-been-granted-european-patent-number-ep3773544-titled-phospholipid-flavagline-conjugates-and-methods-of-using-the-same-for-targeted-cancer-therapy
Cellectar Biosciences Has Been Granted Eur...
07/23/2025 19:58:51

https://data.epo.org/publication-server/publications/pdf?path=2025/30/DOC/EPNWB1/EP19784548NWB1/EP19784548NWB1.pdf

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/01/2025 17:05:56

cellectar-biosciences-prices-6m-offering-of-865k-class-a-units-and-335k-class-b-units-with-warrants-exercisable-at-525-price-per-class-a-unit-is-500-and-the-price-per-class-b-unit-is-499999
Cellectar Biosciences Prices $6M Offering ...
07/01/2025 13:27:11

Cellectar Biosciences, Inc.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION